CertiK and RootData reached a strategic partnership aimed at making "security and transparency" hard metrics for trust in the industry.
ChainCatcher reports that CertiK and RootData have announced a strategic partnership to jointly launch a dual benchmark brand plan for security and transparency. The initiative aims to drive “security + transparency” as dual hard metrics in the Web3 industry’s trust system.
CertiK is a global leader in Web3 security services, and its Skynet platform conducts multidimensional security assessments through a security scoring system. RootData is an industry-leading Web3 asset data platform, having developed an innovative transparency scoring model covering aspects such as token economics, team background, and compliance audits.
In this collaboration, CertiK will leverage RootData’s standardized data interface to enrich the dimensions and coverage of its security ratings. RootData will rely on CertiK’s professional security assessment capabilities to provide authoritative calibration for its transparency scores. Together, the two parties will promote the dual evaluation standards of “CertiK Skynet Score + RootData Transparency Score,” offering a reliable reference standard featuring both security and transparency to project teams, exchanges, investment institutions, and users.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
